This is an aggregated industry headline. Read the full story at Endpoints News →
Hikma and Amarin's generic drug case heads to Supreme Court arguments
When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications on how new generics get ...
By Endpoints News
· Apr 28, 2026
· via Endpoints News
Image: Endpoints News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
policyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
PolicyBriefing
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
PolicySTAT News ↗
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…